Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis According to Disease Characteristics and Maintenance Therapies

During the SARS-CoV-2 vaccination campaign, people with CF (pwCF) were considered a clinically vulnerable population. However, data on the immunogenicity of anti-SARS-CoV-2 vaccines in pwCF are lacking. We conducted a prospective study enrolling all patients aged > 12 and who were followed-up in...

Descripción completa

Detalles Bibliográficos
Autores principales: Alicandro, Gianfranco, Daccò, Valeria, Cariani, Lisa, Rosazza, Chiara, Sciarrabba, Calogero Sathya, Ferraro, Federica, Lanfranchi, Chiara, Medino, Paola, Girelli, Daniela, Colombo, Carla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406081/
https://www.ncbi.nlm.nih.gov/pubmed/36009545
http://dx.doi.org/10.3390/biomedicines10081998

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406081/
https://www.ncbi.nlm.nih.gov/pubmed/36009545
http://dx.doi.org/10.3390/biomedicines10081998

Ejemplares similares